Long-term glucocorticoid treatment in patients with polymyalgia rheumatica: can we just move a step forward? Comments on “Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis”
Author:
- 30 August 2021
- journal article
- letter
- Published by Springer Nature in Clinical Rheumatology
- Vol. 40 (10) , 4367-4368
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysisClinical Rheumatology, 2021
- Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?Clinical and Experimental Rheumatology, 2021
- C‐reactive protein concentrations as predictors of glucocorticoid‐free remission in patients with polymyalgia rheumaticaInternational Journal of Rheumatic Diseases, 2021
- Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis—prevalence and clinical approachRheumatology, 2020
- Polymyalgia rheumatica with normal values of both erythrocyte sedimentation rate and C-reactive protein concentration at the time of diagnosisRheumatology, 2019
- The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severityBMC Musculoskeletal Disorders, 2011
- Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease.2001
- Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis - A prospective two-year study in 273 patientsScandinavian Journal of Rheumatology, 2001
- The adrenal steroid status in relation to inflammatory cytokines (interleukin‐6 and tumour necrosis factor) in polymyalgia rheumaticaRheumatology, 2000